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Abstract
Background and Aims: Conventional follow-up of teenagers with inflammatory bowel diseases 
[IBD] is done during scheduled outpatient visits regardless of how well the patient feels. We 
designed a telemonitoring strategy for early recognition of flares and compared its efficacy with 
conventional follow-up.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), 
which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact jour-
nals.permissions@oup.com
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Methods: We used a multicentre randomized trial in patients aged 10–19  years with IBD in 
clinical remission at baseline. Participants assigned to telemonitoring received automated alerts 
to complete a symptom score and send a stool sample for measurement of calprotectin. This 
resulted in an individual prediction for flare with associated treatment advice and test interval. In 
conventional follow-up the health check interval was left to the physician’s discretion. The primary 
endpoint was cumulative incidence of disease flares. Secondary endpoints were percentage of 
participants with a positive change in quality-of-life and cost-effectiveness of the intervention.
Results: We included 170 participants [84 telemonitoring; 86 conventional follow-up]. At 52 weeks 
the mean number of face-to-face visits was significantly lower in the telemonitoring group compared 
to conventional follow-up [3.6 vs 4.3, p < 0.001]. The incidence of flares [33 vs 34%, p = 0.93] and 
the proportion of participants reporting positive change in quality-of-life [54 vs 44%, p = 0.27] were 
similar. Mean annual cost-saving was €89 and increased to €360 in those compliant to the protocol.
Conclusions: Telemonitoring is as safe as conventional follow-up, and reduces outpatient visits and 
societal costs. The positive impact on quality-of-life was similar in the two groups. This strategy is 
attractive for teenagers and families, and health professionals may be interested in using it to keep 
teenagers who are well out of hospital and ease pressure on overstretched outpatient services.
Trial registration: NTR3759 [Netherlands Trial Registry]
Key Words:  Telemonitoring; e-health; cost-effectiveness
1. Introduction
Inflammatory bowel disease [IBD], consisting of Crohn’s disease and 
ulcerative colitis, is a chronic, relapsing disorder of the gastrointes-
tinal tract. Inflammation waxes and wanes over time in a seemingly 
unpredictable fashion. Treatment is aimed at inducing and maintain-
ing disease remission and at preserving functional status and qual-
ity-of-life.1 Approximately 50% of patients with IBD have a disease 
course that is typically described by a decline in severity after a fierce 
onset of symptoms, while the other half experience a deterioration 
or persistence of chronic symptoms.2,3
Follow-up of patients with IBD traditionally consists of regular 
prescheduled visits regardless of how well the patient feels. Disease 
flares are most likely to occur at times between scheduled visits.
Twenty per cent of patients with IBD is diagnosed before the age 
of 20 years,4,5 and the incidence is increasing.6 Health professionals 
confronted with the increased disease burden may be interested in 
finding ways to ease the pressure on overstretched outpatient clinics 
with new approaches to monitor disease activity in IBD.
Telephone and Internet technologies are currently widely avail-
able to measure disease activity at a distance.7 Patients can share dis-
ease activity information electronically with their care provider and 
receive feedback between hospital visits. In this way patients could 
be seen at times of clinical need and specialist services could become 
more efficient. In adults with IBD, telemonitoring programmes led to 
earlier recognition of disease flares, better quality-of-life and lower 
healthcare costs.7,8 The feasibility of home telemonitoring in teenag-
ers is less well known. Although their cognitive ability and capacity 
to reason are similar to those of adults, they may have inner conflicts 
regarding autonomy that can result in poor compliance to the moni-
toring protocol and more adverse outcomes.9
We designed a home telemonitoring strategy for teenagers with 
IBD to recognize flares at an early stage and compared its efficacy 
and cost-effectiveness with conventional follow-up.
2. Materials and Methods
2.1. Study design and conduct
We performed a multicentre, randomized controlled, open label trial 
with two parallel groups and a follow-up time of 52  weeks. For 
allocation concealment, randomization was carried out using a sepa-
rate list of computer-generated random allocation numbers for each 
individual participating centre [involving permuted blocks with a 
ratio of 1:1 allocation]. The study was registered in the Netherlands 
Trial Registry [NTR3759] before recruitment of the first par-
ticipant, and the study protocol was published in an open access 
journal.10 The trial was conducted according to the principle of the 
Declaration of Helsinki [59th version, October 2008] and in accord-
ance with the Dutch Medical Research Involving Human Subjects 
Act. The Medical Ethical Committee of the University Medical 
Centre Groningen approved the study protocol [METC 2013/010]. 
Secondary approval was obtained from all participating centres. All 
parents or legal guardians and participants aged 12–19 years gave 
informed consent prior to randomization.
2.2. Participants
Patients between 10 and 19  years old with IBD were eligible for 
inclusion in case of clinical disease remission for at least 3 months 
before study enrolment. IBD had to be diagnosed according to 
Revised Porto criteria more than 6  months before enrolment.11 
Participants were required to have access to a telephone, the 
Internet and an email address, and to have a good knowledge of the 
Dutch language. We excluded patients who were treated with anti-
tumour necrosis factor [TNF] monoclonal antibodies [because of 
unavoidable frequent contact with healthcare providers], had an ile-
ostomy or ileoanal pouch, or had any other comorbidity requiring 
frequent hospital visits. Patients were recruited in 11 centres in the 
Netherlands [six tertiary care hospitals and five large regional gen-
eral hospitals]. National treatment guidelines12 provided uniformity 
in treatment among centres. First choice maintenance therapy in 
patients with Crohn’s disease included a thiopurine or methotrex-
ate. Maintenance therapy in patients with ulcerative colitis was 
aminosalicylate monotherapy or combination therapy with a thio-
purine. Participants with active Crohn’s disease during the study 
period were treated with steroids and gradual dose tapering, or 
with an exclusive oral polymeric diet for 6  weeks. Participants with 
active ulcerative colitis during the study period were treated with 
steroids and aminosalicylate dose escalation. Anti-TNF monoclo-
nal antibodies were indicated after failure of conventional therapy 
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[step-up], and the moment of initiating anti-TNF therapy was con-
sidered a censoring date. Specialists or IBD nurses identified eligible 
patients in their clinic, and these potential participants received an 
information pack containing a patient invitation letter, a participant 
information sheet and consent forms. During the enrolment visit 
the treating specialist checked whether the patient was in clinical 
remission.
2.3. Intervention and control
Participants assigned to the experimental arm of the trial received 
automated email alerts to fill in the symptom score and to send in a 
stool sample. We used an online disease-specific clinical composite 
score (Pediatric Ulcerative Colitis Activity Index [PUCAI]13 and the 
shortened Pediatric Crohn’s Disease Activity Index [shPCDAI]).14,15 
Stool samples were sent to the hospital laboratory of the coordinat-
ing study centre and were analysed immediately after arrival with 
a calprotectin point-of-care test [Quantum Blue® Calprotectin, 
Bühlmann Laboratories], based on lateral flow technology offer-
ing quantitative results within minutes.16 The results of both the 
symptom score and the calprotectin stool test were uploaded on the 
IBD-live website and cumulated in a colour-coded disease flare risk 
stratification [Figure 1, flarometer] that was visible to the individual 
participant and the local IBD team. The participant was in the low-
risk stratum when the symptom score was below 10 and stool calpro-
tectin was below 250 µg/g. Participants in this low-risk stratum were 
reassured and advised to retest in 3 months. In the intermediate-risk 
stratum a shorter test interval was advised before progressing to a 
decision. Symptomatic participants with calprotectin values above 
250 µg/g were considered to have a high risk of disease flare and 
were advised to contact their specialist. If the participant failed to 
complete the symptom score, two additional automated reminders 
were sent in the next 2  weeks. After denial of three email alerts par-
ticipants were contacted personally by phone or email. Participants 
in the home telemonitoring arm had health checks in the consul-
tation room of the specialist for adverse effects of the medication 
every 6 months. Participants assigned to conventional follow-up had 
regular checks in the consultation room as before the trial regardless 
of how well the patient was, and the interval varied according to the 
physician’s discretion. When a participant experienced a flare, rapid 
access to specialist care was provided for all participants. A health 
check included, among others, a physician’s rating of disease activity 
and blood sampling.
2.4. Outcomes
The primary outcome was the cumulative incidence of disease 
flares per group, defined as disease activity necessitating therapy 
intensification [including steroid therapy, exclusive enteral nutri-
tion, aminosalicylate dose escalation or introduction of anti-TNF 
antibodies]. Secondary outcomes were the change in quality-of-
life and cost-effectiveness measured from a societal perspective. 
Quality-of-life was measured with the IBD-specific IMPACT-III 
questionnaire, which comprises 35 questions that were answered 
with a Likert scale [0–4]. The total score and six subdomain scores 
[bowel symptoms, systemic symptoms, emotional symptoms, social 
functioning, body image, treatment/interventions] are presented in 
a range from 0 to 100, with higher scores representing a higher 
quality-of-life.17–19 The cost-effectiveness analysis incorporated all 
direct and indirect medical and non-medical costs. In addition to 
our previously published study protocol,10 we determined predic-
tors of compliance to the home telemonitoring programme, defined 
as being compliant to 80% or more of the alerts [whether or not 
after a personal encouragement by email or phone]. Candidate pre-
dictors were age, gender, type of disease, time since last relapse, 
travel distance to the hospital, highest education level of one of 
the parents and emotional quotient [EQ]. EQ was measured with 
the Dutch translation of the Bar-On EQ-inventory: Youth Version 
[Toronto, Canada], which consists of 60 questions subdivided 
into five domains [intrapersonal, interpersonal, adaptability, stress 
management and general mood].20 We used the overall EQ score. 
Participants with high scores represented effectiveness in deal-
ing with daily demands. Finally, we asked the participants in the 
home telemonitoring group to give their opinion on participation 
in telemonitoring. Each item was scored on a five-point Likert scale 
ranging from strongly agree to strongly disagree.
High
Action required
1
month
Consider
step-up
Consider other
diagnostic tests
1
month
3 months
Contct your doctor
Not sure whether
your IBD is under
control
Your IBD is
under control
Intermediate
Low
Probability of
disease are
Symptom
score >10
Calprotectin
>250 μg/g
Message Timing
next test
No shift to
lower stratum?
Figure 1. Flarometer. Algorithm with advice on treatment and the timing of re-measurement.
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2.5. Sample size
To detect a 15% reduction in the absolute relapse risk after 52 weeks 
of follow-up with a two-sided significance level of 5% and with 80% 
power, we calculated that we needed 90 participants per group [tak-
ing into account a maximum of 10% loss-to-follow-up].
2.6. Randomization and masking
Participants for whom consent or assent was provided were ran-
domly allocated in a 1:1 ratio to one of the two arms of the study 
according to a computer-generated random sequence stratified by 
research site and disease type [Crohn’s disease vs ulcerative coli-
tis], and using blocks of variable size. The allocation sequence was 
generated by the biostatistics unit of the University Medical Centre 
Groningen, and was not available to any member of the research 
team. Allocation concealment was ensured, as the study website 
[https://www.ibd-live.nl] did not release the randomization code 
until the participant had been recruited into the trial. The nature of 
the intervention did not allow blinding of participants, care provid-
ers or outcome assessors.
2.7. Statistical analysis
Analysis was conducted according to CONSORT guidelines, fol-
lowing an analysis plan agreed in advance by the independent Data 
Safety Monitoring Board. We used descriptive statistics to compare 
baseline characteristics of trial participants by allocated arm. The 
primary analyses were conducted according to intention-to-treat, 
meaning that all participants recruited into the study were analysed 
within the group [home telemonitoring or conventional follow-up] to 
which they were randomized, irrespective of what care they actually 
received. Secondary analyses were conducted on a per-protocol base. 
These analyses were restricted to those participants who were com-
pliant to the study protocol. Participants in the home telemonitoring 
group were considered compliant when they had replied to 80% or 
more of the alerts [whether or not after a personal encouragement by 
phone], while participants in conventional follow-up were considered 
compliant when they had sent in at least two of three requested stool 
samples for calprotectin measurement. Participants were analysed 
as randomized without imputation of missing data. As previously 
published web-based programmes have focused on patients with 
ulcerative colitis,21–23 we decided a priori to do a subgroup analysis to 
examine the intervention in two subtypes of IBD, i.e. ulcerative coli-
tis and Crohn’s disease. Time-to-flare was plotted in a Kaplan–Meier 
curve and tested with a two-sided log rank test. We calculated qual-
ity-of-life changes scores per group after 52 weeks of follow-up and 
the proportion of participants per group with a positive change. The 
cost-effectiveness analysis was performed from a societal perspective 
[also incorporating costs of travel to the hospital and costs of leave 
from work of the parents] using unit prices from Dutch Guidelines 
[see Supplementary Table 1]. The outcome variables of the cost-effec-
tiveness analysis were the number of relapses within 1 year and the 
quality-of-life change scores from baseline. Results of 5000 bootstrap 
replications were calculated using R version 3.2.0 [R Foundation for 
Statistical Computing] and are presented in a cost-effectiveness plane. 
Predictors of good adherence to home telemonitoring were assessed 
by calculating odds ratios with the use of univariate logistic regression 
analysis. Participants’ opinions about the telemonitoring programme 
are presented as diverging stacked bar charts using Microsoft Excel 
2007.24 All data were analysed electronically using SPSS version 22.0 
for Windows [SPSS] and were presented with GraphPad Prism ver-
sion 5 for Windows [GraphPad Software].
2.8. Patient involvement
The Dutch Crohn’s and Colitis patient organization [CCUVN] was 
involved from the inception of the study. The Director was consulted 
for advice regarding the study design and was on the committee that 
decided on the ZonMw funding. All participants received a sum-
mary of the results.
3. Results
3.1. Description of participants
Participants were recruited between June 6, 2013 and January 15, 
2016. Of 295 teenagers who received information about the study, 
170 were eligible and randomly allocated to the home telemonitoring 
[n = 84] or conventional follow-up [n = 86] arms [Figure 2]. Baseline 
characteristics are presented in Table  1. The two trial arms were 
well balanced except for an overrepresentation of males assigned to 
home telemonitoring. We did not conduct statistical adjustments for 
this imbalance. Good compliance to the study protocol [response to 
≥ 80% of automated alerts] was observed in 48 participants [57%] 
assigned to home telemonitoring and in 72 participants [84%] 
assigned to conventional follow-up [Figure 2].
3.2. Primary outcome
During 52 weeks of follow-up, 28 participants (33%, 95% confi-
dence interval [CI] 24–44%) in the home telemonitoring arm and 29 
[34%, 95% CI 24–44%] in the conventional follow-up arm expe-
rienced one or more disease flares [Figure 3]. There was no differ-
ence in time-to-flare between groups, either in the intention-to-treat 
analysis or in the per-protocol analysis [respectively p = 0.932 and 
0.908]. Subgroup analysis according to disease type did not show a 
difference in time-to-flare either [data not shown].
3.3. Secondary outcomes
3.3.1. Quality of life
In the intention-to-treat analysis, the mean quality-of-life change 
score from baseline was +1.32 in the home telemonitoring group 
compared to −0.32 in the conventional follow-up group [p = 0.27]. 
A  total of 54% of participants in the home telemonitoring group 
reported a positive change during 52 weeks of follow-up compared 
to 44% in the conventional group [p = 0.27] [Figure 4].
3.3.2. Cost-effectiveness
Participants assigned to home telemonitoring had fewer face-to-face 
encounters with their care provider compared to those in conven-
tional follow-up [3.6 vs 4.3, p < 0.001]. Also, the number of times 
blood was taken, trips to the hospital and hours of absence from 
school or social activities were lower in the home telemonitoring 
group. On the other hand, the total numbers of abdominal sonog-
raphy studies in participants with Crohn’s disease and stool exami-
nations were increased in the telemonitoring group [Supplementary 
Table 2]. In Figure 5 we present cost-effectiveness planes for the out-
comes total number of relapses and quality-of-life change score after 
52 weeks of follow-up, both in an intention-to-treat and per-pro-
tocol analysis. Home telemonitoring was cost-effective, as it dem-
onstrated comparable effectiveness with conventional follow-up at 
lower costs. Home telemonitoring led to a mean annual cost-saving 
of €89 per participant in the intention-to-treat analysis. The inter-
vention was most cost-saving in participants who were compliant 
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to the telemonitoring schedule, corresponding with a mean annual 
cost-saving of €360 per participant.
3.3.3. Predictors of compliance to the home telemonitoring 
programme
In Figure 6 we show that factors associated with compliance to the 
home telemonitoring programme were a higher EQ (odds ratio [OR] 
1.3, 95% CI 1.1–1.5) and a longer travel distance [OR 1.2, 95% CI 
1.0–1.5].
3.3.4. Participants’ opinion about home telemonitoring
Fifty-nine of 84 participants gave their opinion about participat-
ing in the home telemonitoring programme [Figure  7]. Forty-four 
respondents [75%] were compliant to 80% or more of the alerts. 
The majority of respondents agreed that home telemonitoring is 
time-saving [96%], increased their understanding of the disease 
[56%] and did not disturb them [79%]. Seventy-one per cent wished 
to continue with home telemonitoring care.
4. Discussion
4.1. Main findings and relevance
This study shows that calprotectin-based home telemonitoring of 
teenagers with clinically stable IBD at baseline is a safe and cost-
saving alternative to conventional follow-up. The results for the pri-
mary outcome [time-to-flare] were not different between the two 
follow-up strategies, regardless of intention-to-treat or per-protocol 
analysis. For participants and their parents in the intervention arm, 
the time-saving aspect of home telemonitoring and the better sense 
of disease control were highly valued. We postulate that the cost-
saving effect of home telemonitoring could have been larger if the 
Medical Ethical Committee has allowed use of a larger test interval 
for patients on immunomodulators [complete blood count and liver 
enzymes] or aminosalicylates [creatinine]. These blood tests were 
done in the participating IBD centres, and not at the primary care 
level. Although not evidence-based, many clinicians believe that 
these tests should be performed with an interval of 3–6 months.1,25 
We are of the opinion that these blood tests can be performed 
125 patients
excluded
(declined participation or
are at baseline)
295 patients
checked for
eligilibity
170 patients
randomized
84
Home
telemonitoring
74
participants
48 participants
compliant
(≥ 80% response to
e-mail alerts)
72 participants
compliant
(≥ 2 fecal
calprotectin results)
Per protocol
Intention to treat
R
andom
ization
E
ligibility
14 participants were
insufciently compliant
10 participants did not
respond to any e-mail alert
26 participants were
insufciently compliant
86
Conventional
follow-up
Figure 2. Study flow chart presenting the number of participants who were included in the intention-to-treat and per-protocol analyses. Definition of compliant 
was ≥80% response to e-mail alerts in the home telemonitoring group and two or more faecal calprotectin measurements in the conventional follow-up group.
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with wider intervals in teenagers with stable IBD without dose 
escalations.
In this study we used the flarometer score as a non-invasive esti-
mate of the probability of a disease flare. The flarometer score is a 
clinical composite score consisting of the participant’s answers to a 
validated disease activity questionnaire and the result of the stool 
calprotectin test [Figure 1]. The concept of the flarometer was evalu-
ated in a prospective study among teenagers with IBD and had better 
predictive value than a composite score with C-reactive protein.26 
Home telemonitoring with a non-invasive predictor of disease flare 
is a fundamental change in the way to follow teenagers with IBD. 
Schedules for follow-up have traditionally been rigid [e.g. checks in 
the consultation room of the specialist at fixed intervals], but we 
have shown that home telemonitoring can move IBD care into a 
new era in which teenagers take ownership of their chronic disease 
and participate in the therapeutic decision-making process based on 
longitudinal tracking of flarometer results.
4.2. Comparison with other studies
The results of this multi-centre randomized controlled trial among 
Dutch teenagers with IBD are consistent with a recently published 
single-centre study among 53 Danish teenagers with IBD.27 The 
Danish study had a similar design as our study with a longer obser-
vation period, but with smaller group size. The authors also con-
cluded that telemonitoring is safe, without causing an increase in 
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Figure 4. Waterfall plot illustrating each participant’s change in quality-of-life 
[IMPACT-III] score during 52 weeks. The horizontal axis across the plot serves as 
the baseline measure; vertical bars are drawn for each participant. Vertical bars 
that are below the line represent participants with worsening scores, while 
bars above the line represent those who experienced improvement of quality-
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Figure 3. Primary outcome: cumulative risk of disease flares in participants 
assigned to home telemonitoring and conventional follow-up [intention-to-
treat analysis].
Table 1. Baseline characteristics of participants allocated to home telemonitoring or conventional follow-up; values are percentages [num-
bers] unless otherwise stated
Characteristic Home telemonitoring [n = 84] Conventional follow-up [n = 86]
Median [IQR] age at enrolment, years 15 [12–16] 15 [13–17]
Male gender 64 [54] 45 [39]
Type of disease
 Ulcerative colitis 54 [45] 51 [44]
 Crohn’s disease 46 [39] 49 [42]
Median [IQR] age at diagnosis, years 12 [9–13] 13 [9–15]
Median [IQR] time since last disease flare, months 13 [7–29] 15 [8–30]
Disease flare in last 12 months before enrolment 46 [39] 42 [36]
Median [IQR] stool calprotectin at enrolment, µg/g 140 [79–408] 160 [100–584]
Taking immunomodulator 69 [58] 65 [56]
Taking aminosalicylate 57 [48] 52 [45]
Emotional quotient
 low [≤89]  5 [4] 5 [4]
 average [90–109] 27 [23] 30 [26]
 high [≥110] 46 [39] 51 [44]
 missing 21 [18] 14 [12]
Median [range] travel distance, km 30 [2–116] 25 [1–142]
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Figure 5. Secondary outcome: cost-effectiveness [intention-to-treat and per-protocol analysis]. Planes present total costs and effects for home telemonitoring 
care compared to conventional follow-up. Positive costs or effects mean home telemonitoring is more expensive or more effective compared to conventional 
follow-up. Effects in [A] are defined as the total number of relapses and in [B] as the individual change in quality-of-life from baseline to end of the study. The 
black dots in the middle correlate with the point estimates of our data. Blue diamonds represent the outcome of 5000 bootstrap replications.
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Figure 6. Odds ratios and 95% confidence intervals for factors associated with better compliance in participants followed by home telemonitoring. Factors with 
an odds ratio >1 were more common in participants who were compliant to 80% or more of the alerts. * Binary variables were coded 0 for no, or 1 for yes. High 
education was defined as pre-university, senior secondary general, university or higher professional level.
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disease activity or treatment escalation compared with conventional 
follow-up.
Both studies showed that not all participants are suitable to be 
followed in a telemonitoring programme. It is important to real-
ize that differences exist in people’s desire for information. Some 
patients seek as much information as possible about the threat of 
a disease flare [‘monitors’], while others try to avoid potentially 
threatening information [‘blunters’].28 Home telemonitoring will 
give the former category of patients and parents a greater sense 
of control, as opposed to the latter category who may feel more 
vulnerable due to the constant confrontation with their chronic 
disease. This aspect may partially explain attrition in the telemoni-
toring arm. A possible solution to this problem is to position telem-
onitoring as checks for wellness rather than as temporary reprieves 
from eventual illness.
4.3. Strengths and limitations
In a recent systematic review on eHealth technologies in IBD it 
was concluded that the majority of published trials had a small 
sample size, were single-centre and only addressed feasibility.7 
Methodological shortcomings of these studies included heteroge-
neity of outcome measures, lack of clinician/patient input, lack of 
validation against conventional symptom scores and limited cost–
benefit analyses.7,29 Our study had a large sample size that enhanced 
internal validity, whereas the multi-centre recruitment in both aca-
demic and general hospitals enhanced external validity. Additionally, 
we provided data on the effect of telemonitoring on the cumulative 
incidence of flares and change in quality-of-life and linked these out-
comes to costs. We considered direct costs of healthcare delivery, 
and indirect cost savings [improved parental work productivity and 
reduced school absenteeism] in the calculation. We are reasonably 
certain of our effect estimates, as we enrolled a cohort of clinically 
stable participants that represents approximately 50% of the spec-
trum of teenage IBD patients. Furthermore, we ran the trial at two 
levels of hospital care and therefore assume that the annual inci-
dence of disease flares in our study cohort is a true reflection of what 
happens in the real world.
The results of this randomized controlled trial come from a 
category of patients and parents who had an interest in home 
telemonitoring and may not be representative of all teenage IBD 
patients. In particular, the patients and parents who participated 
in the trial may have been more eager to learn about telephone 
and Internet technologies to monitor disease activity and thus dif-
fer in important ways from parents and adolescents who chose 
not to participate. The most common reason for declining par-
ticipation was related to a preference for direct contact with the 
specialist.
Secondly, the participation rate, which is the percentage of eligi-
ble participants who eventually participated in the trial, varied con-
siderably per centre. It was highest in the centre that initiated the 
study [77%] and ranged between 13 and 73% in the other centres. 
We have no reasons to believe that the interest in telemonitoring 
among eligible participants varied per centre, but think that the spe-
cialist’s dedication to the monitoring programme may have varied 
from centre to centre.
Thirdly, we used a stool calprotectin value below 250 µg/g as 
a target for disease remission. There is no agreement among IBD 
experts as to whether these are the optimal thresholds, indicating the 
need for prospective and randomized studies comparing monitoring 
strategies that vary in thresholds to strike a balance between under- 
and over-treatment.
Finally, the use of the flarometer score has limitations as it partly 
relies on a self-reported symptom score. This was illustrated in three 
participants who reported high symptom scores together with fae-
cal calprotectin values in the target range. This discrepancy was 
observed in participants with superposed irritable bowel syndrome 
and created so much confusion culminating in withdrawing one par-
ticipant from the experimental arm of the trial on the specialist’s 
advice. This participant continued with conventional follow-up, out-
side the scope of this study.
4.4. Implications for clinicians, patients and 
policy-makers
The number of telemonitoring initiatives for IBD care is ris-
ing.7,8,21,23,27,30–36 Home telemonitoring is a practical method for 
follow-up care in teenagers with a relatively stable course of IBD 
prior to inclusion. A calprotectin drift away from the target range 
in asymptomatic patients is frequently a prelude to a disease flare 
within the next 2–3  months, while consecutive normal values are 
associated with a high probability to remain in remission for the 
next 2–3 months.37 Whether pre-emptive treatment of asymptomatic 
teenagers with increased calprotectin values prevents progression to 
E-mail alerts were not
annoying to me
Telemonitoring provided
better insight in my IBD
Telemonitoring gave me a better
sense of control
Participating in a telemonitoring
program improved my drug adherence
Participating in a telemonitoring
program was less time-consuming
than conventional follow-up
If telemonitoring were the new
standard, I would denitely join in
100% 0%
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
100%
Figure 7. Participants’ opinions about home telemonitoring. The proportion of patients who agreed to the statements [left of the neutral line] vs those who 
disagreed [right of the neutral line].
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an overt flare in the short term and progressive bowel damage in the 
long term could be the focus of a future trial.
It is a misconception that the use of home telemonitoring to follow 
disease activity over time will greatly diminish the workload of the spe-
cialist, as all generated data must be reviewed critically and, if needed, 
actions must be taken. To maintain a successful home telemonitoring 
follow-up programme, a joined collaboration is warranted between 
motivated patients, parents and specialists.38,39 Characteristics that 
were significantly more common among compliant participants were 
a higher emotional quotient and a long travel distance to the hospital. 
We hypothesize that the emotionally more mature participants value 
the better sense of disease control, while those living further away 
from the hospital value the time-saving aspect of home telemonitor-
ing. We recommend offering the telemonitoring service especially to 
teenagers who have at least one of these characteristics, and not to 
those who have a preference for direct contact with the specialist.
Desktop medical activities not linked to a face-to-face contact are 
currently not reimbursable under typical fee-for-service contractual 
and regulatory arrangements. Home telemonitoring activities such 
as described in this project – reviewing generated data and respond-
ing to patients’ emails – are of high value to the delivery system and 
to patients, so the design of gastroenterology practices and reim-
bursement policies should reflect this value.
Home telemonitoring is attractive for teenagers and their fami-
lies, and health professionals may be interested in using it to keep 
teenagers who are well out of hospital and to ease the pressure on 
overstretched outpatient services.
5. Conclusions
Follow-up of teenagers with IBD by home telemonitoring is as safe as 
conventional follow-up, and reduces outpatient visits and societal costs. 
The positive impact on quality-of-life was similar in the two groups.
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